Siegfried Holding AG

2025 group sales rose 4.3% in local currency to CHF 1.33 billion, with 53% of revenue captured in H2. Reported core EBITDA margin was 23.5%; excluding a CHF 7.5 million one-off, core EBITDA margin was 23.05%. Management also said core gross profit was CHF 354 million, core EBITDA was CHF 312.3 million, operating cash flow was up 35% year over year, and strategic investments totaled CHF 231 million. Net debt to core EBITDA was 1.5x at year-end and 1.0x as of yesterday after working-capital conversion. For 2026, Siegfried guided to low-single-digit group growth, high-single-digit Drug Products growth, low-single-digit Drug Substances growth, and core EBITDA margin above 23%, excluding the pending acquisition; management said the acquisition would significantly increase guidance once closing timing is known. Currency was expected to be a top-line headwind of a bit more than 2% for the full year, or about 2.8% in the first half, and first-half seasonality was expected to be roughly 47% to 53% H1/H2.

Marcel Imwinkelried struck an upbeat tone and framed 2025 as proof that the EVOLVE+ strategy is working, emphasizing commercial excellence, operational excellence, and margin expansion. He said Siegfried is ahead of plan in many dimensions, with 30% more new projects/customers won in 2025 versus 2024, plus progress in safety, quality, sustainability, and site expansions. He also highlighted the Noramco/Extractas deal as strategically important for U.S. supply-point needs and said the company is well positioned for midterm growth.

Reto Suter focused on record profitability, strong cash generation, and balance-sheet flexibility. He said 2025 sales were CHF 1.33 billion, operating cash flow rose 35%, strategic investments were CHF 231 million, and year-end net debt/core EBITDA was 1.5x, improving to 1.0x after year-end as roughly CHF 150 million of receivables converted to cash. He also explained the CHF 7.5 million one-off, the CHF 300 million bond, the CHF 40 million non-recourse factoring use within a CHF 50 million facility, and shareholder returns via a proposed CHF 0.4 per share par value repayment.

Analysts focused heavily on the lower 2026 Drug Substance growth guide and the pending confirmation on a large existing commercial product. Management said the customer has been a partner for 30 years, the product is already in market and has been manufactured for years, and the uncertainty is about short-term demand visibility, not customer relationship; they also said the margin is contractually protected. Questions also covered Drug Products growth drivers, GLP-1/protein degrader exposure, seasonality, FX, and the acquisition; management said Drug Products growth is broad-based across dosage forms and sites, that the three recent wins were protein degraders, and that the new acquisition should materially lift guidance once closing timing is set.